Oxidation of pyridine nucleotides during Fas- and ceramide-induced apoptosis in Jurkat cells:: correlation with changes in mitochondria, glutathione depletion, intracellular acidification and caspase 3 activation

被引:101
作者
Petit, PX
Gendron, MC
Schrantz, N
Métivier, D
Kroemer, G
Maciorowska, Z
Sureau, F
Koester, S
机构
[1] CHU Cochin Port Royal, Inst Cochin Genet Mol, INSERM, U129, F-75014 Paris, France
[2] Univ Paris 07, Inst Jacques Monod, Serv Cytometrie Flux, F-75005 Paris, France
[3] INSERM, U131, IPSC, F-92140 Clamart, France
[4] CNRS, UPR 420, F-94801 Villejuif, France
[5] Inst Curie, Dept Pathol, F-75248 Paris 05, France
[6] Beckman Coulter Inc, Adv Technol, Miami, FL 33196 USA
关键词
Bcl-2; cell death; mitochondrial transmembrane potential; permeability transition; redox status;
D O I
10.1042/0264-6021:3530357
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Jurkat T cells showed a major, early decrease in blue auto-fluorescence in response to Fas/Apo-1/CD95 cross-linking or stimulation with cell-permeant ceramide. This indicates the oxidation/depletion of NADH or NADPH before the onset of apoptosis, Kinetic studies, cytofluorimetric multiparameter analyses and cell sorting experiments indicated a close temporal relationship between NAD(P)H oxidation/depletion and the dissipation of the mitochondrial transmembrane potential (Delta Psi (m)). In contrast. NAD(P)H depletion was detected well before several other changes associated with late apoptosis, including enhanced superoxide generation, phosphatidylserine exposure on the cell surface, loss of cytosolic K+, decreased cytoplasmic pH, nuclear DNA fragmentation, cell shrinkage, loss of viability and the appearance of the mitochondrial antigen APO2.7. Full activation of caspase 9 and caspase 3 appeared to be correlated with the appearance of superoxide anions in the mitochondria, and followed the drop in NADPH. Overexpression of the apoptosis-inhibitory proto-oncogene Bcl-2, which encodes an inhibitor of the mitochondrial permeability transition (PT) pore, delayed both the Delta Psi (m) disruption and the depletion of NAD(P)H. Similar effects were observed with the pharmacological PT pore inhibitors, bongkrekic acid and cyclosporin A. Thus there appears to be a close functional relationship between mitochondrial and cellular redox changes during early apoptosis; events that are inhibited by Bcl-2.
引用
收藏
页码:357 / 367
页数:11
相关论文
共 55 条
[1]   Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore.: Implication for regulation of permeability transition by the kinases [J].
Beutner, G ;
Rück, A ;
Riede, B ;
Brdiczka, D .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1998, 1368 (01) :7-18
[2]  
Brambilla L, 1998, J PHARMACOL EXP THER, V284, P1112
[3]   Communication -: Superoxide in apoptosis -: Mitochondrial generation triggered by cytochrome c loss [J].
Cai, JY ;
Jones, DP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (19) :11401-11404
[4]   Mitochondrial perturbations define lymphocytes undergoing apoptotic depletion in vivo [J].
Castedo, M ;
Macho, A ;
Zamzami, N ;
Hirsch, T ;
Marchetti, P ;
Uriel, J ;
Kroemer, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (12) :3277-3284
[5]  
Castedo M, 1996, J IMMUNOL, V157, P512
[6]   RECRUITMENT OF MITOCHONDRIAL CYCLOPHILIN TO THE MITOCHONDRIAL INNER MEMBRANE UNDER CONDITIONS OF OXIDATIVE STRESS THAT ENHANCE THE OPENING OF A CALCIUM-SENSITIVE NONSPECIFIC CHANNEL [J].
CONNERN, CP ;
HALESTRAP, AP .
BIOCHEMICAL JOURNAL, 1994, 302 :321-324
[7]   SELECTIVE-INHIBITION OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE AT THE OXIDATION-REDUCTION SENSITIVE DITHIOL BY MONOBROMOBIMANE [J].
COSTANTINI, P ;
CHERNYAK, BV ;
PETRONILLI, V ;
BERNARDI, P .
FEBS LETTERS, 1995, 362 (02) :239-242
[8]   Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites [J].
Costantini, P ;
Chernyak, BV ;
Petronilli, V ;
Bernardi, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (12) :6746-6751
[9]  
Dallaporta B, 1998, J IMMUNOL, V160, P5605
[10]  
Dellinger M, 1998, BIOTECHNOL APPL BIOC, V28, P25